Bergen, 15 August 2024: Reference is made to the stock exchange announcement
made by BerGenBio ASA (the "Company") on 23 May 2024 regarding the Company's
general meeting resolving a share capital decrease by reducing the nominal value
of the Company's shares by NOK 9 from NOK 10 to NOK 1, resulting in a decrease
of the Company's share capital by NOK 351,784,044, from NOK 390,871,160 to NOK
39,087,116.

The resolution was announced by the Norwegian Register of Business Enterprises
on 28 May 2024, whereafter followed a six-week creditor notice period. The
creditor period has been completed without objections.

The share capital reduction has now been registered with the Norwegian Register
of Business Enterprises (Nw.: Foretaksregisteret). Following such registration
the Company's share capital is NOK 39,087,116 divided into 39,087,116 shares and
voting rights, each share with a nominal value of NOK 1.

For further information, please contact:

Martin Olin, CEO, BerGenBio AS

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

About BerGenBio ASA
BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate bemcentinib a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and severe respiratory infections. BerGenBio is based in Bergen, Norway with a
subsidiary in Oxford, UK. The Company is listed on the Oslo Stock Exchange
(ticker: BGBIO). For more information, visit www.bergenbio.com.

This information is subject to the disclosure requirements pursuant to Section 5
-8 and 5-12 of the Norwegian Securities Trading Act.